Interleukin‐4 induces a CD44(high)/CD49b(high) PC3 subpopulation with tumor‐initiating characteristics

Por Erb, Holger H.H., Guggenberger, Fabian, Santer, Frédéric R., Culig, Zoran
Publicado no J Cell Biochem (2018)

Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways

Por Oh, Su Jung, Erb, Holger H H, Hobisch, Alfred, Santer, Frédéric R, Culig, Zoran
Publicado em 2012

Inhibition of the glucocorticoid receptor results in an enhanced miR-99a/100-mediated radiation response in stem-like cells from human prostate cancers

Por Rane, Jayant K., Erb, Holger H.H., Nappo, Giovanna, Mann, Vincent M., Simms, Matthew S., Collins, Anne T., Visakorpi, Tapio, Maitland, Norman J.
Publicado no Oncotarget (2016)

IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα(2) through IRF9

Por Erb, Holger H H, Langlechner, Regina V, Moser, Patrizia L, Handle, Florian, Casneuf, Tineke, Verstraeten, Karin, Schlick, Bettina, Schäfer, Georg, Hall, Brett, Sasser, Kate, Culig, Zoran, Santer, Frédéric R
Publicado em 2013

Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy

Por Santer, Frédéric R., Erb, Holger H. H., Oh, Su Jung, Handle, Florian, Feiersinger, Gertrud E., Luef, Birgit, Bu, Huajie, Schäfer, Georg, Ploner, Christian, Egger, Martina, Rane, Jayant K., Maitland, Norman J., Klocker, Helmut, Eder, Iris E., Culig, Zoran
Publicado no Oncotarget (2015)